Health
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Data across AbbVie's blood cancer portfolio will be featured in multiple oral and poster presentations including investiga
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of difficult-to-treat blood cancers ","length":236,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":236,"olType":false},{"type":"text","content":"NORTH CHICAGO, Ill., Dec. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Data across AbbVie's blood cancer portfolio will be featured in multiple oral and poster presentations including investigational compounds etentamig (ABBV-383) and PVEK (pivekimab sunirine), as well as approved therapies EPKINLY® (epcoritamab-bysp) and VENCLEXTA® (venetoclax).","length":709,"tagName":"p"},{"type":"text","content":""These ASH presentations reinforce AbbVie's leadership in advancing the potential next wave of blood cancer innovation, with clinical data that highlight our commitment to raising the standard of care," said Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumor and hematology at AbbVie. "The data also highlights the depth and diversity of our pipeline and portfolio of approved medicines spanning across T-cell engagers, BCL-2 Inhibitors and ADCs, all designed to address the heterogeneity of blood cancers for a range of patients."","length":581,"tagName":"p"},{"type":"text","content":"Key data from epcoritamab, venetoclax-based treatments, etentamig and PVEK to be highlighted as oral presentations demonstrate promising efficacy, durable responses, and safety profiles across multiple hematologic malignancies and lines of therapy:","length":248,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fixed-Duration epcoritamab (CD20×CD3 Bispecific T-Cell Engager) in combination with rituximab and lenalidomide (R2) in Relapsed or Refractory FL ","length":144,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Results...